Related Experiment Video

Updated: Jul 14, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of

Giuseppe De Luca1, Harry Suryapranata, Gregg W Stone

  • 1Division of Cardiology, Maggiore della Carità Hospital, Eastern Piedmont University, C.So Mazzini, 18, 24100 Novara, Italy. giuseppe.deluca@maggioreosp.novara.it

International Journal of Cardiology
|June 5, 2007
PubMed

Insights

Coronary stenting in acute myocardial infarction (AMI) reduces target vessel revascularization but not overall mortality. However, stenting offers mortality benefits for high-risk patients, identified by risk scores.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Coronary stenting is used in acute myocardial infarction (AMI) to reduce target vessel revascularization (TVR).
  • The impact of stenting on mortality and reinfarction in AMI remains unclear.
  • Previous meta-analyses have not included all available randomized trials.

Purpose of the Study:

  • To conduct an updated meta-analysis evaluating coronary stenting benefits in AMI.
  • To assess the effects of stenting on mortality, reinfarction, and TVR.
  • To determine if benefits correlate with patient risk profiles.

Main Methods:

  • Systematic literature search of MEDLINE and CENTRAL databases (1990-2006).
  • Inclusion of all completed, published randomized trials of coronary stenting for AMI.
  • Extraction of data on study design, stent type, patient characteristics, and clinical outcomes by two independent investigators.

Main Results:

  • Analysis of 13 randomized trials with 6922 patients; 50% received stents, 50% balloon angioplasty.
  • Stenting showed no significant reduction in 30-day or 1-year mortality compared to balloon angioplasty.
  • Significant TVR reduction with stenting at 30 days and 6-12 months; no difference in reinfarction rates.
  • Mortality benefits of stenting correlated with patient risk profile at 30 days and 1 year.

Conclusions:

  • Coronary stent implantation in AMI may be considered for TVR benefits.
  • Stenting may reduce mortality in high-risk AMI patients.
  • Validated risk scores can help identify high-risk patients who may benefit from stenting.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...